• BioVal BioStock Analytics initiated coverage of SynAct Pharma under a research engagement with the company.
• The analysis values resomelagon in rheumatoid arthritis, respiratory viral infections and dengue at SEK 2.9 billion (USD 295 million).
• The combined valuation reflects risk-adjusted net present values, with most assigned to rheumatoid arthritis.
• An FDA Type C meeting request addresses a potential pivotal Phase 3 design; feedback is expected by early 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SynAct Pharma AB published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.